Literature DB >> 33387817

Response Inhibition Deficits in Women with the FMR1 Premutation are Associated with Age and Fall Risk.

Carly Moser1, Lyndsay Schmitt1, Joseph Schmidt2, Amanda Fairchild3, Jessica Klusek4.   

Abstract

One in 113-178 females worldwide carry a premutation allele on the FMR1 gene. The FMR1 premutation is linked to neurocognitive and neuromotor impairments, although the phenotype is not fully understood, particularly with respect to age effects. This study sought to define oculomotor response inhibition skills in women with the FMR1 premutation and their association with age and fall risk. We employed an antisaccade eye-tracking paradigm to index oculomotor inhibition skills in 35 women with the FMR1 premutation and 28 control women. The FMR1 premutation group exhibited longer antisaccade latency and reduced accuracy relative to controls, indicating deficient response inhibition skills. Longer response latency was associated with older age in the FMR1 premutation and was also predictive of fall risk. Findings highlight the utility of the antisaccade paradigm for detecting early signs of age-related executive decline in the FMR1 premutation, which is related to fall risk. Findings support the need for clinical prevention efforts to decrease and delay the trajectory of age-related executive decline in women with the FMR1 premutation during midlife.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Antisaccade; Executive function; FXTAS; Falls; Fragile X premutation

Mesh:

Substances:

Year:  2020        PMID: 33387817      PMCID: PMC7945960          DOI: 10.1016/j.bandc.2020.105675

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  69 in total

1.  Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome.

Authors:  S Cohen; K Masyn; J Adams; D Hessl; S Rivera; F Tassone; J Brunberg; C DeCarli; L Zhang; J Cogswell; D Loesch; M Leehey; J Grigsby; P J Hagerman; R Hagerman
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

2.  Prevalence of CGG expansions of the FMR1 gene in a US population-based sample.

Authors:  Marsha Mailick Seltzer; Mei Wang Baker; Jinkuk Hong; Matthew Maenner; Jan Greenberg; Daniel Mandel
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-22       Impact factor: 3.568

3.  Visual pathway deficit in female fragile X premutation carriers: a potential endophenotype.

Authors:  Szabolcs Kéri; György Benedek
Journal:  Brain Cogn       Date:  2008-09-11       Impact factor: 2.310

4.  Associations between gait speed and well-known fall risk factors among community-dwelling older adults.

Authors:  Ingebjørg Lavrantsdatter Kyrdalen; Pernille Thingstad; Leiv Sandvik; Heidi Ormstad
Journal:  Physiother Res Int       Date:  2018-09-10

5.  Executive control deficits as a prodrome to falls in healthy older adults: a prospective study linking thinking, walking, and falling.

Authors:  Talia Herman; Anat Mirelman; Nir Giladi; Avraham Schweiger; Jeffrey M Hausdorff
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-19       Impact factor: 6.053

6.  The predictability of saccadic latency in a novel voluntary oculomotor task.

Authors:  P E Hallett; B D Adams
Journal:  Vision Res       Date:  1980       Impact factor: 1.886

7.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

Review 8.  Falls and gait disorders in geriatric neurology.

Authors:  Hubertus Axer; Martina Axer; Heinrich Sauer; Otto W Witte; Georg Hagemann
Journal:  Clin Neurol Neurosurg       Date:  2010-01-20       Impact factor: 1.876

9.  Inhibition deficits are modulated by age and CGG repeat length in carriers of the FMR1 premutation allele who are mothers of children with fragile X syndrome.

Authors:  Jessica Klusek; Jinkuk Hong; Audra Sterling; Elizabeth Berry-Kravis; Marsha R Mailick
Journal:  Brain Cogn       Date:  2019-12-27       Impact factor: 2.310

10.  Behavioral and Neural Plasticity of Ocular Motor Control: Changes in Performance and fMRI Activity Following Antisaccade Training.

Authors:  Sharna D Jamadar; Beth P Johnson; Meaghan Clough; Gary F Egan; Joanne Fielding
Journal:  Front Hum Neurosci       Date:  2015-12-18       Impact factor: 3.169

View more
  5 in total

1.  Low normal FMR1 genotype in older adult women: Psychological well-being and motor function.

Authors:  Jessica Klusek; Roger Newman-Norlund; Amanda J Fairchild; Sarah Newman-Norlund; Sara Sayers; Jill C Stewart; Elizabeth Berry-Kravis; Julius Fridriksson
Journal:  Arch Gerontol Geriatr       Date:  2022-08-12       Impact factor: 4.163

2.  Maternal Pragmatic Language Difficulties in the FMR1 Premutation and the Broad Autism Phenotype: Associations with Individual and Family Outcomes.

Authors:  Jessica Klusek; Angela John Thurman; Leonard Abbeduto
Journal:  J Autism Dev Disord       Date:  2021-04-04

3.  Verbal inhibition declines among older women with high FMR1 premutation expansions: A prospective study.

Authors:  Nell Maltman; Jessica Klusek; Leann DaWalt; Jinkuk Hong; Audra Sterling; Elizabeth Berry-Kravis; Marsha R Mailick
Journal:  Brain Cogn       Date:  2022-03-10       Impact factor: 2.682

4.  Delineating the Relationships Between Motor, Cognitive-Executive and Psychiatric Symptoms in Female FMR1 Premutation Carriers.

Authors:  Darren R Hocking; Danuta Z Loesch; Paige Stimpson; Flora Tassone; Anna Atkinson; Elsdon Storey
Journal:  Front Psychiatry       Date:  2021-12-03       Impact factor: 4.157

5.  Family history of FXTAS is associated with age-related cognitive-linguistic decline among mothers with the FMR1 premutation.

Authors:  Jessica Klusek; Amanda Fairchild; Carly Moser; Marsha R Mailick; Angela John Thurman; Leonard Abbeduto
Journal:  J Neurodev Disord       Date:  2022-01-14       Impact factor: 4.074

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.